CBD combined with a minor cannabinoid reduced colitis severity in mice through a specific receptor pathway
A 20:1 combination of CBD and cannabidivarin (CBDV) reduced colitis severity in mice by suppressing the immune cell trafficking receptor CXCR4 through the CB2 receptor.
Quick Facts
What This Study Found
The CBD:CBDV 20:1 combination significantly reduced CXCR4 expression in multiple immune cell types, impaired chemotaxis, and improved disease activity, colon length, and histological outcomes in DSS-induced colitis. All benefits were abolished in CB2 knockout mice.
Key Numbers
CBD:CBDV ratio of 20:1. CXCR4 reduction confirmed across three cell types. Benefits absent in CB2 knockout mice.
How They Did This
In vitro experiments in MOLT-4 cells, murine splenocytes, and human PBMCs. In vivo DSS-induced colitis model in wild-type and CB2 knockout mice. CB2 receptor inhibition confirmed mechanism.
Why This Research Matters
This provides a mechanistic explanation for the "entourage effect" in a specific disease context. The minor cannabinoid CBDV enhanced CBD's therapeutic effect through a defined molecular pathway.
The Bigger Picture
The entourage effect has been debated for years with limited mechanistic evidence. This study provides one of the clearest demonstrations that a specific minor cannabinoid enhances a major cannabinoid through a defined receptor mechanism.
What This Study Doesn't Tell Us
DSS-induced colitis is a chemical model that does not fully replicate human IBD. The 20:1 ratio was tested but other ratios were not systematically compared.
Questions This Raises
- ?Would the CBD:CBDV combination show similar benefits in other IBD models?
- ?Is the 20:1 ratio optimal?
Trust & Context
- Key Stat:
- ratio that suppressed CXCR4 immune trafficking receptor via CB2, reducing colitis severity in mice
- Evidence Grade:
- Strong mechanistic validation using both in vitro and in vivo models plus CB2 knockout confirmation.
- Study Age:
- 2025 publication.
- Original Title:
- Combination of CBD with minor cannabinoid CBDV suppresses CXCR4 via CB2 receptor and alleviates colitis in mice.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 193, 118768 (2025)
- Authors:
- Gelfand, Anat(2), Besser, Elazar, Procaccia, Shiri(2), Cohen, Jonathan, Steinberg, Miryam, Kleifeld, Oded, Meiri, David
- Database ID:
- RTHC-06519
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is CBDV?
Cannabidivarin (CBDV) is a minor cannabinoid found in cannabis, structurally similar to CBD but present in smaller amounts. This study shows it can enhance CBD's anti-inflammatory effects.
What is the entourage effect?
The theory that cannabinoids work better together than alone. This study provides concrete evidence: the CBD-CBDV combination suppressed an immune trafficking receptor through CB2, with CBDV identified as a modulator of CBD's effect.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06519APA
Gelfand, Anat; Besser, Elazar; Procaccia, Shiri; Cohen, Jonathan; Steinberg, Miryam; Kleifeld, Oded; Meiri, David. (2025). Combination of CBD with minor cannabinoid CBDV suppresses CXCR4 via CB2 receptor and alleviates colitis in mice.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 193, 118768. https://doi.org/10.1016/j.biopha.2025.118768
MLA
Gelfand, Anat, et al. "Combination of CBD with minor cannabinoid CBDV suppresses CXCR4 via CB2 receptor and alleviates colitis in mice.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. https://doi.org/10.1016/j.biopha.2025.118768
RethinkTHC
RethinkTHC Research Database. "Combination of CBD with minor cannabinoid CBDV suppresses CX..." RTHC-06519. Retrieved from https://rethinkthc.com/research/gelfand-2025-combination-of-cbd-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.